{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:51:50Z","timestamp":1793199110420,"version":"4.5.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40120-017-0086-4","type":"journal-article","created":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T06:28:26Z","timestamp":1513232906000},"page":"59-85","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":394,"title":["Vitamin D and Multiple Sclerosis: A Comprehensive Review"],"prefix":"10.1007","volume":"7","author":[{"given":"Martina B.","family":"Sintzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Rametta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Reder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,14]]},"reference":[{"issue":"23","key":"86_CR1","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1001\/jama.296.23.2832","volume":"296","author":"K Munger","year":"2006","unstructured":"Munger K, Levin L, Hollis B, Howard N, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296(23):2832.","journal-title":"JAMA"},{"issue":"12","key":"86_CR2","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1177\/1352458511425366","volume":"17","author":"K Munger","year":"2011","unstructured":"Munger K, Ascherio A. Prevention and treatment of MS: studying the effects of vitamin D. Mult Scler J. 2011;17(12):1405\u201311.","journal-title":"Mult Scler J."},{"issue":"5","key":"86_CR3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/jamaneurol.2015.4800","volume":"73","author":"K Munger","year":"2016","unstructured":"Munger K, \u00c5ivo J, Hongell K, Soilu-H\u00e4nninen M, Surcel H, Ascherio A. Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish maternity cohort. JAMA Neurol. 2016;73(5):515.","journal-title":"JAMA Neurol."},{"key":"86_CR4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","volume":"96","author":"AC Ross","year":"2011","unstructured":"Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"86_CR5","unstructured":"ChemSpider | Search and share chemistry [Internet]. Chemspider.com. 2017 [cited 30 June 2016]. http:\/\/www.chemspider.com ."},{"key":"86_CR6","unstructured":"Conlan R, Sherman E. Unraveling the enigma of vitamin D [Internet]. National Academy of Sciences; 2000 [cited 28 June 2016]. http:\/\/www.nasonline.org\/publications\/beyond-discovery\/vitamin-d.pdf ."},{"issue":"6","key":"86_CR7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1474-4422(10)70086-7","volume":"9","author":"A Ascherio","year":"2010","unstructured":"Ascherio A, Munger K, Simon K. Vitamin D and multiple sclerosis. Lancet Neurol. 2010;9(6):599\u2013612.","journal-title":"Lancet Neurol."},{"issue":"2","key":"86_CR8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/jcb.10338","volume":"88","author":"M Holick","year":"2002","unstructured":"Holick M. Vitamin D: a millenium perspective. J Cell Biochem. 2002;88(2):296\u2013307.","journal-title":"J Cell Biochem"},{"key":"86_CR9","unstructured":"Health Quality Ontario. Clinical Utility of Vitamin D Testing: An Evidence-Based Analysis. 2010 p. 1-93."},{"issue":"1","key":"86_CR10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/nu5010111","volume":"5","author":"M Wacker","year":"2013","unstructured":"Wacker M, Holick M. Vitamin D\u2014effects on skeletal and extraskeletal health and the need for supplementation. Nutrients. 2013;5(1):111\u201348.","journal-title":"Nutrients."},{"issue":"7","key":"86_CR11","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"M Holick","year":"2011","unstructured":"Holick M, Binkley N, Bischoff-Ferrari H, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911\u201330.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"86_CR12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cellimm.2012.10.002","volume":"279","author":"L Yang","year":"2012","unstructured":"Yang L, Ma J, Zhang X, Fan Y, Wang L. Protective role of the vitamin D receptor. Cell Immunol. 2012;279(2):160\u20136.","journal-title":"Cell Immunol"},{"issue":"7","key":"86_CR13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.mayocp.2013.05.011","volume":"88","author":"A Hossein-nezhad","year":"2013","unstructured":"Hossein-nezhad A, Holick M. Vitamin D for health: a global perspective. Mayo Clin Proc. 2013;88(7):720\u201355.","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"86_CR14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nri2378","volume":"8","author":"J Mora","year":"2008","unstructured":"Mora J, Iwata M, von Andrian U. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol. 2008;8(9):685\u201398.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"86_CR15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1756285612473513","volume":"6","author":"C Pierrot-Deseilligny","year":"2013","unstructured":"Pierrot-Deseilligny C, Souberbielle J. Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis. Ther Adv Neurol Disor. 2013;6(2):81\u2013116.","journal-title":"Ther Adv Neurol Disor."},{"key":"86_CR16","unstructured":"Ross A, Taylor C, Yaktine A, Del Valle H. Dietary reference intakes: calcium and vitamin D. Committee to review dietary reference intakes for vitamin D and calcium food and nutrition board [Internet]. Washington, D.C.: National Academy of Sciences; 2011 [cited 28 June 2016]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK56070\/pdf\/TOC.pdf ."},{"issue":"4","key":"86_CR17","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/ajcn\/84.4.694","volume":"84","author":"L Houghton","year":"2006","unstructured":"Houghton L, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. The Am J Clin Nutr. 2006;84(4):694\u20137.","journal-title":"The Am J Clin Nutr."},{"issue":"4","key":"86_CR18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/jcb.10423","volume":"88","author":"S Christakos","year":"2003","unstructured":"Christakos S, Dhawan P, Liu Y, Peng X, Porta A. New insights into the mechanisms of vitamin D action. J Cell Biochem. 2003;88(4):695\u2013705.","journal-title":"J Cell Biochem"},{"issue":"3","key":"86_CR19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","volume":"357","author":"M Holick","year":"2007","unstructured":"Holick M, Vitamin D. Deficiency. N Engl J Med. 2007;357(3):266\u201381.","journal-title":"N Engl J Med"},{"issue":"6","key":"86_CR20","doi-asserted-by":"crossref","first-page":"1706S","DOI":"10.1093\/ajcn\/80.6.1706S","volume":"80","author":"R Heaney","year":"2004","unstructured":"Heaney R. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr. 2004;80(6):1706S\u20139S.","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"86_CR21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/ajcn\/77.1.204","volume":"77","author":"R Heaney","year":"2003","unstructured":"Heaney R, Davies K, Chen T, Holick M, Barger-Lux M. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutri. 2003;77(1):204\u201310.","journal-title":"Am J Clin Nutri."},{"issue":"23","key":"86_CR22","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1212\/WNL.0b013e3181e1cec2","volume":"74","author":"J Burton","year":"2010","unstructured":"Burton J, Kimball S, Vieth R, et al. A phase I\/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74(23):1852\u20139.","journal-title":"Neurology."},{"issue":"3","key":"86_CR23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ajcn\/86.3.645","volume":"86","author":"S Kimball","year":"2007","unstructured":"Kimball S, Ursell M, O\u2019Connor P, Vieth R. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr. 2007;86(3):645\u201351.","journal-title":"Am J Clin Nutr"},{"issue":"12","key":"86_CR24","doi-asserted-by":"crossref","first-page":"e15235","DOI":"10.1371\/journal.pone.0015235","volume":"5","author":"J Smolders","year":"2010","unstructured":"Smolders J, Peelen E, Thewissen M, et al. Safety and T Cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One. 2010;5(12):e15235.","journal-title":"PLoS One"},{"issue":"10","key":"86_CR25","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/imj.12269","volume":"43","author":"D Bell","year":"2013","unstructured":"Bell D, Crooke M, Hay N, Glendenning P. Prolonged vitamin D intoxication: presentation, pathogenesis and progress. Int Med J. 2013;43(10):1148\u201350.","journal-title":"Int Med J."},{"issue":"1\u20132","key":"86_CR26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jns.2014.08.019","volume":"346","author":"Y Fragoso","year":"2014","unstructured":"Fragoso Y, Adoni T, Damasceno A, et al. Unfavorable outcomes during treatment of multiple sclerosis with high doses of vitamin D. J Neurol Sci. 2014;346(1\u20132):341\u20132.","journal-title":"J Neurol Sci"},{"issue":"19","key":"86_CR27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1056\/NEJM195205082461901","volume":"246","author":"R Swank","year":"1952","unstructured":"Swank R, Lerstad O, Str\u00f8m A, Backer J. Multiple Sclerosis in Rural Norway. N Eng J Med. 1952;246(19):721\u20138.","journal-title":"N Eng J Med."},{"issue":"4\u20135","key":"86_CR28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1600-0404.1970.tb05806.x","volume":"46","author":"K Westlund","year":"1970","unstructured":"Westlund K. Distribution and mortality time trend of multiple sclerosis and some other diseases in Norway. Acta Neurol Scand. 1970;46(4\u20135):455\u201383.","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"86_CR29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000054783","volume":"20","author":"I Mei van der","year":"2001","unstructured":"van der Mei I, Ponsonby A, Blizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology. 2001;20(3):168\u201374.","journal-title":"Neuroepidemiology."},{"issue":"7","key":"86_CR30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/jnnp.2006.101196","volume":"78","author":"S Vukusic","year":"2006","unstructured":"Vukusic S, Van Bockstael V, Gosselin S, Confavreux C. Regional variations in the prevalence of multiple sclerosis in French farmers. J Neurol Neurosurg Psychiatry. 2006;78(7):707\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"86_CR31","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/brain\/awq147","volume":"133","author":"C Pierrot-Deseilligny","year":"2010","unstructured":"Pierrot-Deseilligny C, Souberbielle J. Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis. Brain. 2010;133(7):1869\u201388.","journal-title":"Brain"},{"issue":"5","key":"86_CR32","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1212\/WNL.0b013e31820a0a9f","volume":"76","author":"S Orton","year":"2011","unstructured":"Orton S, Wald L, Confavreux C, et al. Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology. 2011;76(5):425\u201331.","journal-title":"Neurology."},{"issue":"5","key":"86_CR33","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1212\/WNL.35.5.672","volume":"35","author":"J Kurtzke","year":"1985","unstructured":"Kurtzke J, Beebe G, Norman J. Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MIS. Neurology. 1985;35(5):672.","journal-title":"Neurology."},{"issue":"6","key":"86_CR34","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ana.21141","volume":"61","author":"A Ascherio","year":"2007","unstructured":"Ascherio A, Munger K. Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol. 2007;61(6):504\u201313.","journal-title":"Ann Neurol."},{"issue":"6","key":"86_CR35","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1212\/WNL.0b013e31820af93d","volume":"76","author":"R Lucas","year":"2011","unstructured":"Lucas R, Ponsonby A, Dear K, et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology. 2011;76(6):540\u20138.","journal-title":"Neurology."},{"issue":"3","key":"86_CR36","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.4049\/jimmunol.132.3.1276","volume":"132","author":"S Hauser","year":"1984","unstructured":"Hauser S, Weiner H, Che C, Shapiro M, Gilles F, Letvin N. Prevention of experimental allergic encephalomyelitis (EAE) in the SJL\/J mouse by whole body ultraviolet irradiation. J Immunol. 1984;132(3):1276\u201381.","journal-title":"J Immunol."},{"issue":"7483","key":"86_CR37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/bmj.38301.686030.63","volume":"330","author":"C Willer","year":"2005","unstructured":"Willer C. Timing of birth and risk of multiple sclerosis: population based study. BMJ. 2005;330(7483):120.","journal-title":"BMJ"},{"issue":"10","key":"86_CR38","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00415-014-7241-y","volume":"261","author":"B Fiddes","year":"2014","unstructured":"Fiddes B, Wason J, Sawcer S. Confounding in association studies: month of birth and multiple sclerosis. J Neurol. 2014;261(10):1851\u20136.","journal-title":"J Neurol"},{"issue":"8","key":"86_CR39","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jamaneurol.2016.1463","volume":"73","author":"P Rodr\u00edguez Cruz","year":"2016","unstructured":"Rodr\u00edguez Cruz P, Matthews L, Boggild M, et al. Time- and region-specific season of birth effects in multiple sclerosis in the United Kingdom. JAMA Neurol. 2016;73(8):954.","journal-title":"JAMA Neurol."},{"issue":"1","key":"86_CR40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1212\/01.WNL.0000101723.79681.38","volume":"62","author":"K Munger","year":"2004","unstructured":"Munger K, Zhang S, O\u2019Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62(1):60\u20135.","journal-title":"Neurology."},{"issue":"4","key":"86_CR41","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1212\/WNL.0000000000004140","volume":"89","author":"N Nielsen","year":"2017","unstructured":"Nielsen N, Munger K, Stenager E, Ascherio A. Author response: neonatal vitamin D status and risk of multiple sclerosis: a population-based case-control study. Neurology. 2017;89(4):411.","journal-title":"Neurology."},{"issue":"8","key":"86_CR42","doi-asserted-by":"crossref","first-page":"e1001866","DOI":"10.1371\/journal.pmed.1001866","volume":"12","author":"L Mokry","year":"2015","unstructured":"Mokry L, Ross S, Ahmad O, et al. Vitamin D and risk of multiple sclerosis: a mendelian randomization study. PLOS Med. 2015;12(8):e1001866.","journal-title":"PLOS Med."},{"issue":"17","key":"86_CR43","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1212\/WNL.0000000000003849","volume":"88","author":"M Gianfrancesco","year":"2017","unstructured":"Gianfrancesco M, Stridh P, Rhead B, et al. Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS. Neurology. 2017;88(17):1623\u20139.","journal-title":"Neurology."},{"key":"86_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2017.00265","volume":"8","author":"G Jelinek","year":"2017","unstructured":"Jelinek G. Determining causation from observational studies: a challenge for modern neuroepidemiology. Front Neurol. 2017;8:1\u20133.","journal-title":"Front Neurol."},{"issue":"5","key":"86_CR45","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1212\/NXG.0000000000000097","volume":"2","author":"B Rhead","year":"2016","unstructured":"Rhead B, B\u00e4\u00e4rnhielm M, Gianfrancesco M, et al. Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol Gen. 2016;2(5):e97.","journal-title":"Neurol Gen."},{"issue":"3","key":"86_CR46","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ana.24210","volume":"76","author":"P Ueda","year":"2014","unstructured":"Ueda P, Rafatnia F, B\u00e4\u00e4rnhielm M, et al. Neonatal vitamin D status and risk of multiple sclerosis. Ann Neurol. 2014;76(3):338\u201346.","journal-title":"Ann Neurol"},{"issue":"3","key":"86_CR47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ana.24239","volume":"76","author":"A Ascherio","year":"2014","unstructured":"Ascherio A, Munger K. Not too late to take vitamin D supplements. Ann Neurol. 2014;76(3):321\u20132.","journal-title":"Ann Neurol"},{"issue":"7","key":"86_CR48","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s00415-015-7740-5","volume":"262","author":"G Pihl-Jensen","year":"2015","unstructured":"Pihl-Jensen G, Frederiksen J. 25-Hydroxyvitamin D levels in acute monosymptomatic optic neuritis: relation to clinical severity, paraclinical findings and risk of multiple sclerosis. J Neurol. 2015;262(7):1646\u201354.","journal-title":"J Neurol"},{"issue":"1","key":"86_CR49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1212\/WNL.0000000000003469","volume":"88","author":"R Marrie","year":"2016","unstructured":"Marrie R, Daumer M. A gestational dose of vitamin D per day keeps the MS doctor away. Neurology. 2016;88(1):13\u20134.","journal-title":"Neurology."},{"issue":"3","key":"86_CR50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1212\/WNL.0b013e31825fdec7","volume":"79","author":"T Runia","year":"2012","unstructured":"Runia T, Hop W, de Rijke Y, Buljevac D, Hintzen R. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology. 2012;79(3):261\u20136.","journal-title":"Neurology."},{"issue":"5","key":"86_CR51","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ana.21972","volume":"67","author":"E Mowry","year":"2010","unstructured":"Mowry E, Krupp L, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset MS. Ann Neurol. 2010;67(5):618\u201324.","journal-title":"Ann Neurol"},{"issue":"2","key":"86_CR52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.22043","volume":"68","author":"S Simpson","year":"2010","unstructured":"Simpson S, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in MS. Ann Neurol. 2010;68(2):193\u2013203.","journal-title":"Ann Neurol"},{"issue":"2","key":"86_CR53","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ana.23591","volume":"72","author":"E Mowry","year":"2012","unstructured":"Mowry E, Waubant E, McCulloch C, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012;72(2):234\u201340.","journal-title":"Ann Neurol"},{"issue":"2","key":"86_CR54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ene.12844","volume":"23","author":"E Mowry","year":"2015","unstructured":"Mowry E, Pelletier D, Gao Z, Howell M, Zamvil S, Waubant E. Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection. Eur J Neurol. 2015;23(2):327\u201332.","journal-title":"Eur J Neurol"},{"issue":"9","key":"86_CR55","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/1352458508094399","volume":"14","author":"J Smolders","year":"2008","unstructured":"Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler J. 2008;14(9):1220\u20134.","journal-title":"Mult Scler J."},{"key":"86_CR56","unstructured":"Harandi A, Shahbeigi S, Pakdaman H, Fereshtehnejad S, Nikravesh E, Jalilzadeh R. Association of serum 25(OH) vitamin D3 concentration with severity of multiple sclerosis. Iran J Neurol [Internet]. 2012 [cited 22 August 2017];11(2):54\u201358. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3829240\/ ."},{"issue":"5","key":"86_CR57","first-page":"585","volume":"4","author":"S Shahbeigi","year":"2013","unstructured":"Shahbeigi S, Pakdaman H, Fereshtehnejad S, Jalilzadeh G, Heydari M. Serum Vitamin D3 Concentration Correlates with the Severity of Multiple Sclerosis. Int J Prev Med. 2013;4(5):585\u201391.","journal-title":"Int J Prev Med."},{"issue":"2","key":"86_CR58","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1352458513494959","volume":"20","author":"V Martinelli","year":"2013","unstructured":"Martinelli V, Dalla Costa G, Colombo B, et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler J. 2013;20(2):147\u201355.","journal-title":"Mult Scler J."},{"issue":"3","key":"86_CR59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/WNN.0000000000000009","volume":"26","author":"N Koven","year":"2013","unstructured":"Koven N, Cadden M, Murali S, Ross M. Vitamin D and long-term memory in multiple sclerosis. Cogn Behav Neurol. 2013;26(3):155\u201360.","journal-title":"Cogn Behav Neurol."},{"issue":"3","key":"86_CR60","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamaneurol.2013.5993","volume":"71","author":"A Ascherio","year":"2014","unstructured":"Ascherio A, Munger K, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71(3):306\u201314.","journal-title":"JAMA Neurol."},{"issue":"12","key":"86_CR61","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jamaneurol.2015.2742","volume":"72","author":"K Fitzgerald","year":"2015","unstructured":"Fitzgerald K, Munger K, K\u00f6chert K, et al. Association of Vitamin D Levels With multiple sclerosis activity and progression in patients receiving interferon Beta-1b. JAMA Neurol. 2015;72(12):1458.","journal-title":"JAMA Neurol."},{"issue":"7","key":"86_CR62","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","volume":"67","author":"L Kappos","year":"2006","unstructured":"Kappos L, Polman C, Freedman M, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242\u20139.","journal-title":"Neurology."},{"issue":"9585","key":"86_CR63","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)61194-5","volume":"370","author":"L Kappos","year":"2007","unstructured":"Kappos L, Freedman M, Polman C, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389\u201397.","journal-title":"Lancet"},{"issue":"11","key":"86_CR64","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(09)70237-6","volume":"8","author":"L Kappos","year":"2009","unstructured":"Kappos L, Freedman M, Polman C, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8(11):987\u201397.","journal-title":"Lancet Neurol."},{"issue":"1","key":"86_CR65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","volume":"50","author":"W McDonald","year":"2001","unstructured":"McDonald W, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121\u20137.","journal-title":"Ann Neurol"},{"issue":"2","key":"86_CR66","doi-asserted-by":"crossref","first-page":"124","DOI":"10.17925\/ENR.2015.10.02.124","volume":"10","author":"B Taylor","year":"2015","unstructured":"Taylor B, Moses H, Paul F, Suarez G, Rametta M. Treatment of multiple sclerosis-relationship between Vitamin D and Interferon \u03b2-1b. Eur Neurol Rev. 2015;10(2):124.","journal-title":"Eur Neurol Rev."},{"issue":"8","key":"86_CR67","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/acn3.91","volume":"1","author":"K Munger","year":"2014","unstructured":"Munger K, K\u00f6chert K, Simon K, et al. Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Ann Clin Trans Neurol. 2014;1(8):605\u201317.","journal-title":"Ann Clin Trans Neurol."},{"issue":"3","key":"86_CR68","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1212\/WNL.0b013e31825fded9","volume":"79","author":"N Stewart","year":"2012","unstructured":"Stewart N, Simpson S, van der Mei I, et al. Interferon- and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology. 2012;79(3):254\u201360.","journal-title":"Neurology."},{"issue":"6","key":"86_CR69","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1212\/NXI.0000000000000167","volume":"2","author":"D Rotstein","year":"2015","unstructured":"Rotstein D, Healy B, Malik M, et al. Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e167.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"3","key":"86_CR70","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/WNL.0b013e31825fdf01","volume":"79","author":"K Loken-Amsrud","year":"2012","unstructured":"Loken-Amsrud K, Holmoy T, Bakke S, et al. Vitamin D and disease activity in multiple sclerosis before and during interferon-treatment. Neurology. 2012;79(3):267\u201373.","journal-title":"Neurology."},{"issue":"6","key":"86_CR71","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/08820139.2011.573041","volume":"40","author":"G Mosayebi","year":"2011","unstructured":"Mosayebi G, Ghazavi A, Ghasami K, Jand Y, Kokhaei P. Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest. 2011;40(6):627\u201339.","journal-title":"Immunol Invest"},{"issue":"17","key":"86_CR72","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1212\/WNL.0b013e3182343274","volume":"77","author":"M Stein","year":"2011","unstructured":"Stein M, Liu Y, Gray O, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology. 2011;77(17):1611\u20138.","journal-title":"Neurology."},{"issue":"8","key":"86_CR73","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1177\/1352458511434607","volume":"18","author":"M Kampman","year":"2012","unstructured":"Kampman M, Steffensen L, Mellgren S, J\u00f8rgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler J. 2012;18(8):1144\u201351.","journal-title":"Mult Scler J."},{"key":"86_CR74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/452541","volume":"2012","author":"V Shaygannejad","year":"2012","unstructured":"Shaygannejad V, Janghorbani M, Ashtari F, Dehghan H. Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int. 2012;2012:1\u20137.","journal-title":"Mult Scler Int."},{"issue":"5","key":"86_CR75","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/jnnp-2011-301876","volume":"83","author":"M Soilu-H\u00e4nninen","year":"2012","unstructured":"Soilu-H\u00e4nninen M, \u00c5ivo J, Lindstr\u00f6m B, et al. A randomised, double blind, placebo controlled trial with vitamin D3as an add on treatment to interferon \u03b2-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(5):565\u201371.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"86_CR76","first-page":"67","volume":"14","author":"M Etemadifar","year":"2015","unstructured":"Etemadifar M, Janghorbani M. Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: Preliminary findings of a randomized-controlled trial. Iran J Neurol. 2015;14(2):67\u201373.","journal-title":"Iran J Neurol."},{"issue":"1","key":"86_CR77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-015-0394-1","volume":"15","author":"G Jelinek","year":"2015","unstructured":"Jelinek G, Marck C, Weiland T, Pereira N, van der Meer D, Hadgkiss E. Latitude, sun exposure and vitamin D supplementation: associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis. BMC Neurol. 2015;15(1):1\u20136.","journal-title":"BMC Neurol."},{"key":"86_CR78","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.msard.2016.10.005","volume":"10","author":"J Laursen","year":"2016","unstructured":"Laursen J, S\u00f8ndergaard H, S\u00f8rensen P, Sellebjerg F, Oturai A. Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. Mult Scler Rel Dis. 2016;10:169\u201373.","journal-title":"Mult Scler Rel Dis."},{"key":"86_CR79","doi-asserted-by":"crossref","first-page":"45926","DOI":"10.1038\/srep45926","volume":"7","author":"H Darwish","year":"2017","unstructured":"Darwish H, Haddad R, Osman S, et al. Effect of vitamin D replacement on cognition in multiple sclerosis patients. Sci Rep. 2017;7:45926.","journal-title":"Sci Rep."},{"key":"86_CR80","doi-asserted-by":"crossref","unstructured":"Smolders J, Hupperts R, Vieth R, et al. High dose cholecalciferol (vitamin D3) oil as add-on therapy in subjects with relapsing-remitting multiple sclerosis receiving subcutaneous interferon \u03b2-1a. In: Presented at the European Committee for Treatment and Research in Multiple Sclerosis conference. London, England, September 14\u201317, 2016. Abstract S166.","DOI":"10.1212\/WNL.88.16_supplement.S44.005"},{"key":"86_CR81","unstructured":"Camu W, Pierrot-Deseilligny C, Hautecoeur P, et al. Cholecalciferol supplementation in relapsing multiple sclerosis patients treated with subcutaneous interferon beta-1a: a randomized, controlled trial. In: Presented at the European Committee for treatment and research in multiple sclerosis conference. London, England, September 14\u201317, 2016. Abstract P750."},{"issue":"4","key":"86_CR82","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1212\/WNL.0000000000002316","volume":"86","author":"E Sotirchos","year":"2015","unstructured":"Sotirchos E, Bhargava P, Eckstein C, et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology. 2015;86(4):382\u201390.","journal-title":"Neurology."},{"issue":"12","key":"86_CR83","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"R Fox","year":"2012","unstructured":"Fox R, Miller D, Phillips J, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087\u201397.","journal-title":"N Engl J Med"},{"issue":"5","key":"86_CR84","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"J Cohen","year":"2010","unstructured":"Cohen J, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402\u201315.","journal-title":"N Engl J Med"},{"issue":"12","key":"86_CR85","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1177\/1352458513489756","volume":"19","author":"E James","year":"2013","unstructured":"James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan S. The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Mult Scler J. 2013;19(12):1571\u20139.","journal-title":"Mult Scler J."},{"key":"86_CR86","unstructured":"ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2017 [cited 30 June 2016]. http:\/\/www.clinicaltrials.gov ."},{"issue":"15","key":"86_CR87","first-page":"1","volume":"13","author":"J D\u00f6rr","year":"2012","unstructured":"D\u00f6rr J, Ohlraun S, Skarabis H, Paul F. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials. 2012;13(15):1\u20136.","journal-title":"Trials."},{"issue":"2","key":"86_CR88","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cct.2014.10.004","volume":"39","author":"P Bhargava","year":"2014","unstructured":"Bhargava P, Cassard S, Steele S, et al. The Vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials. 2014;39(2):288\u201393.","journal-title":"Contemp Clin Trials."}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-017-0086-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T18:19:18Z","timestamp":1719685158000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40120-017-0086-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["86"],"URL":"https:\/\/doi.org\/10.1007\/s40120-017-0086-4","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]}}}